BR112022012789A2 - Homólogo de proteína, quito-oligossacarídeo, composição farmacêutica, método de tratamento ou prevenção, ácido nucleico sintético ou recombinante e uso de um homólogo de proteína - Google Patents

Homólogo de proteína, quito-oligossacarídeo, composição farmacêutica, método de tratamento ou prevenção, ácido nucleico sintético ou recombinante e uso de um homólogo de proteína

Info

Publication number
BR112022012789A2
BR112022012789A2 BR112022012789A BR112022012789A BR112022012789A2 BR 112022012789 A2 BR112022012789 A2 BR 112022012789A2 BR 112022012789 A BR112022012789 A BR 112022012789A BR 112022012789 A BR112022012789 A BR 112022012789A BR 112022012789 A2 BR112022012789 A2 BR 112022012789A2
Authority
BR
Brazil
Prior art keywords
protein homolog
oligosaccharide
present
provides
chito
Prior art date
Application number
BR112022012789A
Other languages
English (en)
Inventor
Saiyed Taslimarif
Brijalal Patel Paresh
Ravindran Balachandran
Panda Santosh
Original Assignee
Centre For Cellular And Molecular Platforms
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre For Cellular And Molecular Platforms filed Critical Centre For Cellular And Molecular Platforms
Publication of BR112022012789A2 publication Critical patent/BR112022012789A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

HOMÓLOGO DE PROTEÍNA, QUITO-OLIGOSSACARÍDEO, COMPOSIÇÃO FARMACÊUTICA, MÉTODO DE TRATAMENTO OU PREVENÇÃO, ÁCIDO NUCLEICO SINTÉTICO OU RECOMBINANTE E USO DE UM HOMÓLOGO DE PROTEÍNA. A presente invenção proporciona moléculas terapêuticas para combater sepse. A presente invenção proporciona proteínas capazes de aprimorar a sobrevivência através de imunomodulação em pós-septicemia em mamíferos e oligossacarídeos, capazes de imunomodular inflamação em um mamífero. A presente invenção proporciona homólogo de proteínas de HSP70 humano derivado a partir de nematoide Setaria digitata e suas formas recombinantes e oligossacarídeos e o papel das mesmas em imunomodular a resposta inflamatória em um mamífero. A presente invenção também proporciona uma composição que compreende proteínas terapêuticas e/ou profiláticas e moléculas de oligossacarídeo para imunomodulação em sepse; e método para tratar e/ou evitar sepse, MODS (síndrome de disfunção de múltiplos órgãos) ou choque séptico em um mamífero.
BR112022012789A 2019-12-26 2020-12-26 Homólogo de proteína, quito-oligossacarídeo, composição farmacêutica, método de tratamento ou prevenção, ácido nucleico sintético ou recombinante e uso de um homólogo de proteína BR112022012789A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941053971 2019-12-26
PCT/IB2020/062459 WO2021130729A1 (en) 2019-12-26 2020-12-26 Therapeutic molecules for combating sepsis

Publications (1)

Publication Number Publication Date
BR112022012789A2 true BR112022012789A2 (pt) 2022-09-20

Family

ID=76574046

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012789A BR112022012789A2 (pt) 2019-12-26 2020-12-26 Homólogo de proteína, quito-oligossacarídeo, composição farmacêutica, método de tratamento ou prevenção, ácido nucleico sintético ou recombinante e uso de um homólogo de proteína

Country Status (6)

Country Link
US (1) US20230105103A1 (pt)
EP (1) EP4081223A4 (pt)
KR (1) KR20220132542A (pt)
AU (1) AU2020415493A1 (pt)
BR (1) BR112022012789A2 (pt)
WO (1) WO2021130729A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022185286A1 (en) * 2021-03-05 2022-09-09 Centre For Cellular And Molecular Platforms Therapeutic and/or prophylactic anti-viral agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1261264A (en) * 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
JPS62138496A (ja) * 1985-12-11 1987-06-22 Ihara Chem Ind Co Ltd キチンオリゴマ−の製造方法
US20020198139A1 (en) * 2001-05-17 2002-12-26 Deutschman Clifford S. Method of preventing acute pulmonary cell injury

Also Published As

Publication number Publication date
EP4081223A1 (en) 2022-11-02
EP4081223A4 (en) 2024-03-27
KR20220132542A (ko) 2022-09-30
WO2021130729A1 (en) 2021-07-01
US20230105103A1 (en) 2023-04-06
AU2020415493A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112017016336A2 (pt) proteínas de ligação icos agonistas?
BR112017008165B8 (pt) anticorpo de domínio único direcionado contra um componente intracelular e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR112018007422A2 (pt) anticorpos anti-age e métodos de uso dos mesmos
BR112018003127A2 (pt) purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
Chow et al. Human cathelicidin LL-37-derived peptide IG-19 confers protection in a murine model of collagen-induced arthritis
AR085281A1 (es) Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso
BR112018071167A2 (pt) entrega de beta-sarcoglicano e microrna-29 por vírus adenoassociado e tratamento de distrofia muscular
BR112018010160A8 (pt) inibidor da c1 esterase humana recombinante e usos do mesmo
WO2016112208A3 (en) Topical applications of kv1.3 channel blocking peptides to treat skin inflammation
BR112021023024A2 (pt) Anticorpo contra claudina 18a2 e uso do mesmo
BRPI0510016A (pt) vetor lentiviral recombinante para expressão de uma proteìna de flaviviridae e aplicações do mesmo como vacina
BR112017008525A2 (pt) proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo.
BR112021023957A2 (pt) Peptídeos
BR112022012789A2 (pt) Homólogo de proteína, quito-oligossacarídeo, composição farmacêutica, método de tratamento ou prevenção, ácido nucleico sintético ou recombinante e uso de um homólogo de proteína
BR112015018335A2 (pt) Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas
BR112018008840A8 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
BR112018067747A2 (pt) proteínas de fusão recombinantes de folistatina-fc e uso no tratamento da distrofia muscular de duchenne
AR113134A1 (es) Arni variante
BR112022003745A2 (pt) Proteínas de fusão terapêuticas
EP4342534A3 (en) Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury
BR112018071215A2 (pt) peptídeo para uso no tratamento, melhora ou prevenção de osteoartrite
BR112017022390A2 (pt) composição farmacêutica